News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
848,217 Results
Type
Article (86551)
Company Profile (702)
Press Release (760964)
Multimedia
Podcasts (132)
Webinars (14)
Section
Business (232712)
Career Advice (4128)
Deals (39726)
Drug Delivery (129)
Drug Development (90995)
Employer Resources (198)
FDA (18117)
Job Trends (17342)
News (396519)
Policy (39758)
Tag
Academia (3001)
Academic (2)
Accelerated approval (7)
Adcomms (30)
Allergies (96)
Alliances (56852)
ALS (107)
Alzheimer's disease (1513)
Antibody-drug conjugate (ADC) (166)
Approvals (18073)
Artificial intelligence (340)
Autoimmune disease (30)
Automation (17)
Bankruptcy (405)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (481)
Bladder cancer (88)
Brain cancer (33)
Breast cancer (324)
Cancer (2543)
Cardiovascular disease (213)
Career advice (3535)
Career pathing (34)
CAR-T (185)
Cell therapy (518)
Cervical cancer (22)
Clinical research (73561)
Collaboration (949)
Company closure (2)
Compensation (597)
Complete response letters (30)
COVID-19 (2872)
CRISPR (53)
C-suite (281)
Cystic fibrosis (110)
Data (2460)
Decentralized trials (2)
Denatured (46)
Depression (57)
Diabetes (308)
Diagnostics (6940)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (156)
Drug pricing (136)
Drug shortages (33)
Duchenne muscular dystrophy (109)
Earnings (97349)
Editorial (47)
Employer branding (25)
Employer resources (167)
Events (130433)
Executive appointments (803)
FDA (19596)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (855)
Gene editing (129)
Generative AI (36)
Gene therapy (385)
GLP-1 (870)
Government (5180)
Grass and pollen (6)
Guidances (174)
Healthcare (20894)
Huntington's disease (26)
IgA nephropathy (32)
Immunology and inflammation (158)
Indications (31)
Infectious disease (3037)
Inflammatory bowel disease (159)
Inflation Reduction Act (12)
Influenza (59)
Intellectual property (104)
Interviews (813)
IPO (17843)
IRA (51)
Job creations (5190)
Job search strategy (2861)
Kidney cancer (11)
Labor market (47)
Layoffs (569)
Leadership (24)
Legal (10118)
Liver cancer (82)
Lung cancer (356)
Lymphoma (169)
Machine learning (9)
Management (65)
Manufacturing (382)
MASH (87)
Medical device (14651)
Medtech (14656)
Mergers & acquisitions (22470)
Metabolic disorders (829)
Multiple sclerosis (92)
NASH (23)
Neurodegenerative disease (125)
Neuropsychiatric disorders (36)
Neuroscience (2159)
NextGen: Class of 2025 (7682)
Non-profit (5083)
Now hiring (42)
Obesity (442)
Opinion (276)
Ovarian cancer (85)
Pain (105)
Pancreatic cancer (91)
Parkinson's disease (170)
Partnered (25)
Patents (268)
Patient recruitment (124)
Peanut (51)
People (65379)
Pharmaceutical (143)
Pharmacy benefit managers (24)
Phase I (22708)
Phase II (31948)
Phase III (24051)
Pipeline (1520)
Policy (184)
Postmarket research (3552)
Preclinical (10255)
Press Release (72)
Prostate cancer (115)
Psychedelics (38)
Radiopharmaceuticals (271)
Rare diseases (445)
Real estate (7393)
Recruiting (75)
Regulatory (26858)
Reports (61)
Research institute (2659)
Resumes & cover letters (649)
Rett syndrome (7)
RNA editing (8)
RSV (50)
Schizophrenia (84)
Series A (148)
Series B (99)
Service/supplier (30)
Sickle cell disease (61)
Special edition (20)
Spinal muscular atrophy (166)
Sponsored (34)
Startups (4295)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (59)
The Weekly (84)
Vaccines (829)
Venture capitalists (45)
Weight loss (308)
Women's health (41)
Worklife (20)
Date
Today (144)
Last 7 days (959)
Last 30 days (3775)
Last 365 days (35541)
2025 (13756)
2024 (38139)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1271)
Alabama (62)
Alaska (7)
Arizona (271)
Arkansas (14)
Asia (50198)
Australia (8843)
California (6904)
Canada (2156)
China (588)
Colorado (299)
Connecticut (315)
Delaware (173)
Europe (115242)
Florida (1009)
Georgia (234)
Hawaii (1)
Idaho (64)
Illinois (655)
India (31)
Indiana (349)
Iowa (13)
Japan (183)
Kansas (114)
Kentucky (28)
Louisiana (16)
Maine (72)
Maryland (1008)
Massachusetts (5266)
Michigan (258)
Minnesota (441)
Mississippi (2)
Missouri (93)
Montana (31)
Nebraska (26)
Nevada (72)
New Hampshire (70)
New Jersey (1925)
New Mexico (31)
New York (1934)
North Carolina (1170)
North Dakota (10)
Northern California (2980)
Ohio (229)
Oklahoma (15)
Oregon (48)
Pennsylvania (1500)
Puerto Rico (14)
Rhode Island (36)
South America (1653)
South Carolina (28)
South Dakota (1)
Southern California (2554)
Tennessee (111)
Texas (1034)
United States (26248)
Utah (202)
Virginia (183)
Washington D.C. (73)
Washington State (632)
West Virginia (3)
Wisconsin (75)
There are 848,217 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids
Since Elevidys’ first approval in 2023, experts have been clamoring for more data, particularly in older and non-ambulatory children. New results, presented Friday, show mobility improvements in 8- to 9-year-old patients after one year of follow-up.
May 16, 2025
·
2 min read
·
Tristan Manalac
RNA editing
Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline
Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.
May 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
May 16, 2025
·
4 min read
Press Releases
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
May 16, 2025
·
18 min read
C-suite
Novo Nordisk CEO Jørgensen to Depart With Danish Pharma’s Shares in Freefall
Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares have taken a turn since mid-2024, falling by half in one year.
May 16, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
May 16, 2025
·
11 min read
Press Releases
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
May 16, 2025
·
6 min read
Press Releases
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
May 16, 2025
·
16 min read
Press Releases
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
May 16, 2025
·
5 min read
Press Releases
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 16, 2025
May 16, 2025
·
2 min read
1 of 84,822
Next
